Document text
Principal Investigator: Eric Klann
Organization: NEW YORK UNIVERSITY
Fiscal Year: 2024
Award: $1,062,716
Funding agency: National Institute of Neurological Disorders and Stroke
Project Summary/Abstract
Over the last 15 years, several laboratories, including my laboratory, have identified multiple signaling pathways
that regulate translation via the translation initiation factors eIF4E and eIF2α during protein synthesis-dependent
forms of long-lasting synaptic plasticity and various memory processes in rodents, including the consolidation,
reconsolidation, and extinction of auditory and contextual threat memory. These findings have generated much
excitement because they demonstrate the complex biochemical regulation of translation during synaptic plasticity
and memory. Despite this progress, a number of critical and unresolved questions regarding the requirement for
de novo protein synthesis in memory consolidation remain unanswered. We plan to focus on auditory and
contextual threat memory to determine the cell types in the amygdala and hippocampus, respectively, that
require eIF4E- and eIF2α-dependent translation for memory consolidation, reconsolidation, extinction, and
discrimination. We also plan to examine the cell type-specific requirement for de novo translation in memory
using more complex types of behavioral paradigms, including
Dysregulated translation has been shown by a number of laboratories, including my laboratory, to contribute to
synaptic dysfunction and aberrant behaviors in neurodegenerative diseases such as Alzheimer’s disease (AD)
and neurodevelopmental disorders such as fragile X syndrome (FXS) and autism spectrum disorder (ASD).
However, using molecular approaches to dissect circuit dysfunction in these diseases/disorders has been
lacking. Therefore, we plan to examine the role of cell type-specific translational dysregulation in mouse models
of AD, FXS, and ASD. Moreover, we will identify the inappropriately translated mRNAs and their newly
synthesized protein products using translatomic and de novo proteomic approaches that we developed to identify
mRNAs/proteins that are translated/synthesized improperly in mouse models of AD and FXS.
These questions will be addressed by utilizing the powerful multidisciplinary combination of new groundbreaking
genetically-engineered mice and viruses, electrophysiological recordings, immuno-cytochemistry, innovative
methods to measure de novo protein synthesis in vivo, cell-type specific translational profiling, and de novo
proteomics. The results of these studies will provide fundamental insights into the molecular events in both
excitatory and inhibitory neurons that support consolidation, reconsolidation, and extinction of memory.
Moreover, these studies have the potential to provide therapeutic targets for multiple brain disorders that are
associated with dysregulated translation.
Terms: <AD dementia><AD model><ASD><Address><Affinity><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimer's disease model><Alzheimers Dementia><Ammon Horn><Amygdala><Amygdaloid Body><Amygdaloid Nucleus><Amygdaloid structure><Auditory><Autism><Autistic Disorder><Behavior><Behavioral Paradigm><Biochemical><Brain Diseases><Brain Disorders><Cell Body><Cells><Cognitive Discrimination><Cognitive Retention Disorders><Complex><Cornu Ammonis><Degenerative Neurologic Disorders><Discrimination><Disease><Disorder><Dysfunction><EIF-2 alpha><EIF-2alpha><EIF-2α><Early Infantile Autism><Electrophysiology><Electrophysiology (science)><Encephalon Diseases><Escalante syndrome><Event><Extinction><Fragile X><Fragile X Syndrome><Functional disorder><GEM model><GEMM model><Genetically Engineered Mouse><Hippocampus><Infantile Autism><Initiation Factors><Intracranial CNS Disorders><Intracranial Central Nervous System Disorders><Kanner's Syndrome><Laboratories><Learning><Martin-Bell Syndrome><Martin-Bell-Renpenning syndrome><Measures><Memory><Memory Disorders><Messenger RNA><Methods><Mice><Mice Mammals><Molecular><Murine><Mus><Nervous System Degenerative Diseases><Neural Degenerative Diseases><Neural degenerative Disorders><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurodevelopmental Disorder><Neurologic Degenerative Conditions><Neurological Development Disorder><Neurophysiology / Electrophysiology><Pathway interactions><Peptide Initiation Factors><Physiopathology><Prefrontal Cortex><Primary Senile Degenerative Dementia><Protein Biosynthesis><Proteins><Proteomics><Receptor Protein><Renpenning syndrome 2><Ribo-seq><Ribosomal Peptide Biosynthesis><Ribosomal Protein Biosynthesis><Ribosomal Protein Synthesis><Ribosomes><Rodent><Rodentia><Rodents Mammals><Role><Signal Pathway><Synapses><Synaptic><Synaptic plasticity><Translating><Translation Initiation Factor><Translational Initiation Factor><Translational Regulation><Translations><Virus><X-linked mental deficiency-megalotestes syndrome><X-linked mental retardation with fragile X syndrome><X-linked mental retardation-fragile site 1 syndrome><alpha Subunit Eukaryotic Initiation Factor 2><alzheimer model><amygdaloid nuclear complex><autism spectral disorder><autism spectrum disorder><autism-fragile X (AFRAX) syndrome><autistic spectrum disorder><cell type><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><electrophysiological><excitatory neuron><fra(X) syndrome><fra(X)(28) syndrome><fra(X)(q27) syndrome><fra(X)(q27-28) syndrome><fragile X-mental retardation syndrome><fragile Xq syndrome><fragile site mental retardation 1><genetically engineered mouse model><genetically engineered murine model><hippocampal><immunocytochemistry><in vivo><inhibitory neuron><innovate><innovation><innovative><insight><long term memory><longterm memory><mRNA><mRNA Translation><macro-orchidism-marker X (MOMX) syndrome><macro-orchidism-marker X syndrome><mar(X) syndrome><marker X syndrome><memory consolidation><memory process><memory processing><mental retardation-macroorchidism syndrome><mouse model><multidisciplinary><murine model><neurodegenerative illness><neurodevelopmental disease><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><pathophysiology><pathway><primary degenerative dementia><protein synthesis><receptor><ribosome footprint profiling><ribosome profiling><senile dementia of the Alzheimer type><social role><synapse><therapeutic target><translation>